On October 8, 2026, ENvue Medical, Inc. entered into a Secured Promissory Note and Security Agreement with Alpha Capital Anstalt. Under this agreement, the Lender agreed to provide financing in an aggregate principal amount of up to $1,000,000, to be funded in tranches agreed upon between the Company and the Lender. The Lender funded an initial tranche of $250,000 on the same day.
The promissory note accrues interest at a rate of 10% per annum. If an Event of Default occurs, the interest rate increases to the lesser of 18% per annum or the highest rate permitted by applicable law. The outstanding principal amount, along with accrued interest, is due on December 31, 2026. However, the Lender has the right to extend the maturity date in three-month increments through December 31, 2028. The Company’s obligations are secured by a continuing security interest in substantially all of its assets, including accounts, inventory, certain deposits, intellectual property, and equity ownership of its subsidiaries.
Separately, on October 8, 2026, the Company entered into an Amendment Agreement with holders of at least 70% of the outstanding shares of its Series X Non-Voting Convertible Preferred Stock. This amendment modifies the Certificate of Designations for the Series X Preferred Stock. The Certificate of Amendment lowers the conversion price of the Series X Preferred Stock to $0.50 per share, subject to adjustment as provided in the document. It also amends provisions governing subsequent equity sales, including adjustments to the conversion price upon certain dilutive issuances.
The Company filed the Certificate of Amendment with the Secretary of State of the State of Delaware on October 12, 2026.
